ArticleThe American journal of case reports2025
Rapid Progression of Primary Hepatic Neuroendocrine Carcinoma: A Case Report Demonstrating Drastic Oncological Behavior.
Article in The American journal of case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Impact of alcohol-associated and metabolic dysfunction-associated steatotic liver diseases upon hepatic disorder and carcinogenesis in the current era.World journal of hepatology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND Primary hepatic neuroendocrine neoplasms (PHNENs), including primary hepatic neuroendocrine carcinoma (PHNEC), are extremely rare. PHNENs typically exhibit slow growth, although mixed neuroendocrine-non-neuroendocrine neoplasms have poor prognoses. PHNENs are also challenging to diagnose. CASE REPORT A 73-year-old man underwent plain computed tomography (CT), which incidentally detected a 42-mm solitary hepatic tumor. Serum levels of protein induced by vitamin K absence or antagonist-II (PIVKA-II) were elevated at 138 mAU/mL. Thirteen days later, magnetic resonance imaging (MRI) revealed an enlarged hepatic tumor with tumor thromboses extending into the hepatic and portal veins. No early-phase enhancement was observed. At 18 days, Doppler ultrasound and dynamic CT evaluated the tumor as hypovascular, and a newly swollen solitary lymph node appeared. At 39 days, positron emission tomography (PET)/CT revealed strong uptake in the primary liver tumor and metastatic lymph nodes, with additional distant lymph node metastases emerging. At 49 days, a metastatic cervical lymph node was surgically resected. At 61 days, PHNEC was definitively diagnosed based on histopathological and immunohistochemical assessments. The Ki-67 labeling index was >90%. At 67 days, he was hospitalized to begin chemotherapy, but CT revealed end-stage disease. Palliative treatment was required, and the patient died of cancer 82 days after the initial diagnosis. CONCLUSIONS We have presented a thought-provoking case of PHNEC with rapid oncological progression. To clarify clinical implications (eg, atypical imaging features and diagnostic pitfalls), detailed imaging findings are provided. We anticipate that this case will be informative for clinicians in this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.